An interventional study of Uteroovarian transposition in Colorectal (Colon or Rectal) Cancer, Pelvic Malignancies and Oncofertility, sponsored by University of South Florida. Recruiting at 1 site in United States. Open to female participants aged 18 Months to 40 Months. Per ClinicalTrials.gov, last updated 2026-06-24.
Sponsored by University of South Florida · Not applicable, Interventional, and Treatment
This study is designed as a Phase I clinical trial enrolling female patients aged 18-40 years who have been diagnosed with pelvic malignancies requiring whole pelvic external radiation therapy (WPXRT) and who express interest in preserving fertility and ovarian function.
The trial's primary objective is to assess the feasibility and safety of uterine and ovarian transposition (UOT). Premenopausal women under the age of 40 will undergo UOT using a novel minimally invasive approach.
Feasibility and safety will be evaluated through standardized postoperative assessments, including:
(A) success in mobilizing and repositioning the uterus, ovaries, and fallopian tubes while maintaining vascular integrity; (B) documentation of surgical complications; (C) monitoring the timeliness and adherence to planned WPXRT.
To enhance safety and optimize outcomes, intraoperative imaging with indocyanine green fluorescence and Doppler ultrasonography will be employed.
Short-term success will be defined by technical success in repositioning the uterus and ovaries with preserved vascular integrity, absence of major surgical complications, and timely initiation and completion of WPXRT.
Long-term success will be evaluated by the preservation of fertility.
The study's primary objective is also to evaluate surgical, reproductive, and quality-of-life outcomes following UOT. This objective will determine the procedure's efficacy in preserving ovarian and menstrual function and its potential to support future pregnancies.
Endpoints include:
(A) maintenance of normal premenopausal levels of FSH, LH, AMH, and estradiol at defined postoperative intervals; (B) assessment of menstrual timing, regularity, and characteristics to document return of ovulatory cycles; (C) evaluation of uterine integrity and reproductive potential using pelvic ultrasonography; (D) comprehensive evaluation of patient quality of life encompassing physical, emotional, sexual, and reproductive well-being.
These measures will inform optimization of surgical techniques and provide a foundation for scaling the procedure to a broader population in future studies.
This is a phase I study aimed to evaluate feasibility and safety of utero-ovarian transposition (UOT) in young women undergoing whole pelvic radiation therapy (WPXRT) for treatment of a colorectal or other cancers localized to the pelvis. By comprehensively evaluating real-world outcomes for women undergoing this procedure, the proposed work will lay the groundwork necessary to establish UOT as a viable option for fertility preservation and survivorship for this unique patient population. Rigorous inclusion and exclusion criteria will ensure the selection of appropriate candidates, who will undergo a minimally invasive transposition of their cervix, uterus, tube and ovaries outside the planned radiation fields, thus sparing transposed organs from radiation exposure. Following a brief recovery, the radiation oncology team will proceed with WPXRT to treat each patient's cancer. If chemotherapy is indicated, it will be completed at this time, prior to the second procedure. After completing radiation therapy and/or chemotherapy, the uterus and adnexa will be surgically returned to their normal anatomical position.
This study will assess surgical outcomes for enrolled subjects undergoing this care plan, assess quality of life and the preservation of fertility and uterine receptivity by multiple objective measures.
Throughout the study, patients will be closely monitored for perioperative outcomes, including surgical complications, hospital stay, and quality of life. Patterns of menstruation, as well as levels of key hormones routinely used to assess fertility (FSH, LH, AMH, and estradiol) will be measured at key time points.
Successful UOT will be defined as the ability to complete the procedure and successfully restore a viable uterus and adnexa capable of supporting normal menstruation and fertility post-radiation therapy.
The resumption of menstrual cycles for six months following the procedure will be evaluated. Quality of life will be evaluated at multiple steps as women undergo the proposed procedures as well as throughout the planned 6 months follow up window.
Data generated by this pilot study will provide critical insights into the feasibility, safety, and potential benefits of UOT as a fertility-preserving and ovarian function-conserving option for patients with pelvic malignancies undergoing WPXRT. Moving forward, data from this study will be used not only to build out the programmatic and clinical infrastructure needed to further evaluate the efficacy of UOT, but also to overcome roadblocks to its successful clinical implementation in the future.
1,432 studies on the registry are indexed under Colonic Neoplasms; 357 are open to participants now.
This study's planned enrollment of 26 is below the median of 90 across 1,034 interventional studies indexed under Colonic Neoplasms.
Browse Colonic Neoplasms studies →University of South Florida is the lead sponsor of 333 studies on the registry; 63 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 4 (24%) have results posted.
Counted across the registry records on this site, refreshed daily.
Malignancy: Diagnosis of pelvic malignancies that require radiotherapy, including:
Preoperative Ovarian Function: The patient must have normal ovarian function, demonstrated by specific hormonal values, including:
Exclusion Criteria:
Poor General Health or Comorbidities: Severe medical conditions that contraindicate surgical intervention, that include but not limited to:
Cardiovascular Disease:
Uncontrolled Diabetes Mellitus:
Severe Respiratory Diseases:
Connective Tissue Disorders:
Severe Inflammatory Bowel Disease (IBD):
Steroid dependency:
Unsuitable for Ovarian Function Preservation: Women with signs of poor ovarian reserve, including:
Our study population includes premenopausal women 18-40 years old who are diagnosed with pelvic malignancies, such as rectal, colorectal cancer, and other pelvic malignancies that require radiotherapy and wish to preserve fertility and ovarian function. Subjects will be interested in improving their quality of life and reproductive outcomes without the need to undergo additional reproductive endocrinology interventions. Eligible patients will undergo UOT using a novel minimally invasive approach.
Procedure: Uteroovarian transposition
Uteroovarian transposition involves temporarily relocating the uterus, both ovaries and fallopian tubes outside the planned radiation field. Once WPXRT is complete, a second surgery is performed to return these organs to their natural position in the patient's pelvis.
Also known as: uterine transposition
Success of uterine transposition
Success of uterine transposition (feasibility) will be defined as the percentage of cases in which the uterus, ovaries, and fallopian tubes are successfully mobilized and repositioned as planned without the need for intraoperative conversion. Unit of Measure: Percentage of participants (%) Time Frame: up 30 days postsurgery.
Time frame: From enrollment to completion of surveillance/monitoring at 52 weeks
Postoperative Complications
Postoperative complications will be monitored. All complications will be graded according to the Clavien-Dindo classification system. Unit of Measure: Number of participants with complications.
Time frame: From enrollment to 4 weeks postsurgery
Menstrual Function
Menstrual function will be evaluated by assessing the return of menses, cycle regularity, and ovulatory characteristics through a standardized postoperative questionnaire. Unit of Measure: Percentage of participants (%)
Time frame: From enrollment then at 4, 8, 12 weeks and 52 weeks after surgery
Hormonal Function: Follicle-Stimulating Hormone (FSH)
Hormonal Function will be evaluated by measuring serum levels of FSH Unit of Measure: Hormone concentration: IU/L
Time frame: From enrollment then at 4, 8, 12 weeks and 52 weeks after surgery
Hormonal Function: Luteinizing Hormone (LH)
Hormonal Function will be evaluated by measuring serum levels of LH. Unit of Measure: Hormone concentration: IU/L.
Time frame: From enrollment then at 4, 8, 12 weeks and 52 weeks after surgery
Hormonal Function: Anti-Mullerian Hormone (AMH)
Hormonal Function will be evaluated by measuring serum levels of AMH. Unit of Measure: Hormone concentration: IU/L.
Time frame: From enrollment then at 4, 8, 12 weeks and 52 weeks after surgery
Hormonal Function: Estradiol
Hormonal Function will be evaluated by measuring serum levels of estradiol. Unit of Measure: Hormone concentration: ng/mL.
Time frame: From enrollment then at 4, 8, 12 weeks and 52 weeks after surgery
Quality of Life: FSFI survey
Quality of life will be measured using the FSFI survey. Unit of Measure: FSFI total score.
Time frame: At enrollment then at 12 weeks and 52 weeks after surgery
Quality of Life: EORTC QLC-C30
Quality of life will be measured using the EORTC QLQ-C30. Unit of Measure: EORTC QLQ-C30 score.
Time frame: At enrollment then at 12 weeks and 52 weeks after surgery
Plan to share: Yes — Upon reasonable request, deidentified clinical data generated during the study will be available from the principal investigator, Dr. Vaagn Andikyan.
Supporting information: Study protocol, Sap, Icf
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of South Florida